FindMyKOL
Clinical trialNCT04032717TerminatedPhase 1Interventional

Griffithsin-based Rectal Microbicide for PREvention of Viral ENTry (PREVENT)

NCT04032717 is a phase 1 interventional trial sponsored by Rhonda Brand. As of 21 Nov 2026, it was terminated. It studies Q-Griffithsin enema in HIV Prevention. The registry lists an enrollment of 18 participants at 1 site in 1 country. The registry lists a start date of 10 Jul 2019 and a primary completion date of 4 Feb 2021.

SponsorRhonda BrandEnrollment18HIV Prevention
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04032717
FieldValue
Registry IDNCT04032717
StatusTerminated
PhasePhase 1
Study typeInterventional trial
Lead sponsorRhonda Brand
Enrollment18
Registered sites1
Countries1
ConditionsHIV Prevention
DrugsQ-Griffithsin enema
Start10 Jul 2019
Primary completion4 Feb 2021
Study completion4 Feb 2021
Last update posted6 Jul 2023

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is the first-in-human clinical study to see if a single dose of an investigational enema made from a modified plant protein called Q-Griffithsin is safe, tolerated, and acceptable for use by healthy adults 18-45 years of age who practice receptive anal intercourse.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Pennsylvania, United States1 site
  • Hiv/aids Clinical Research Unit / University of Pittsburgh

    Pittsburgh

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvania: 1 sitePA1New JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Q-Griffithsin enema
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT04032717

Each answer restates registry values shown on this page.

What is NCT04032717?

NCT04032717 is a phase 1 interventional trial sponsored by Rhonda Brand. It studies Q-Griffithsin enema in HIV Prevention.

Who leads NCT04032717?

The registry names Ken Ho, MD (principal investigator, University of Pittsburgh) as the overall official.

Where does NCT04032717 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT04032717 study?

The registered drug and biological interventions are Q-Griffithsin enema.

When did NCT04032717 end?

The registry lists a primary completion date of 4 Feb 2021 and a study completion date of 4 Feb 2021. The sponsor last updated the record on 6 Jul 2023.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.